News

New guidelines: All ALS patients should be offered genetic testing

Every person with amyotrophic lateral sclerosis (ALS) should be offered genetic testing to check for the most common ALS-causing mutations, according to a new set of expert guidelines. “These evidence-based, consensus guidelines will support all stakeholders in the ALS community in navigating benefits and challenges of genetic testing,”…

NLRP3 inhibition alone does not ease ALS inflammation: Study

Inhibiting the NLRP3 inflammasome — an immune system protein complex believed to contribute to the inflammation that drives amyotrophic lateral sclerosis (ALS) — alone was not sufficient to ease spinal cord inflammation in a mouse model of the disease, according to recent research. NLRP3 is overactive in ALS and…

Bryostatin-1 boosts cell survival in lab model of ALS

Bryostatin-1, a molecule being developed to treat amyotrophic lateral sclerosis (ALS), improved cell survival in a lab model of the disease, a new study reports. The therapy is known to activate PKC-epsilon, a protein that’s significantly reduced in ALS patients’ motor cortex, a brain region involved in muscle movement…

Aruna Bio’s AB126 eased inflammation in ALS mouse model

Aruna Bio‘s investigational therapy AB126 significantly eased inflammation in the spinal cord and extended survival in a mouse model of amyotrophic lateral sclerosis (ALS), the company announced. The therapy, which is expected to treat several other neurodegenerative and neuroinflammatory disorders, also significantly reduced the levels of neurofilament…

Awards from Calmes Scholarship Fund help students in ALS families

Having a family member with amyotrophic lateral sclerosis (ALS) can strain household finances as well as the emotions of caregivers and other relatives. To help relieve some of that financial burden, the Jane Calmes ALS Scholarship Fund was established four years ago to support post-high school education for…